Evidence map›Paper›PMID 32525892›Full record

ArticlePloS one2020

HIV-1 pol gene diversity and molecular dating of subtype C from Sri Lanka.

Ajit Patil, Jayanthi P Elwitigala, Lilani Rajapaksa, Raman Gangakhedkar, Devidas Chaturbhuj, Razia Pendse, Dharshani Iruka Rajapaksha, B B Rewari, Nilmini Malliawadu, Kanchana Jayamanna and 2 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 3 countries.

Ajit PatilHIV Drug Resistance Laboratory, National AIDS Research Institute, Pune, India.ORCID 0000-0002-6976-0978
Jayanthi P ElwitigalaNational STD/AIDS Control Programme, Colombo, Sri Lanka.
Lilani RajapaksaNational STD/AIDS Control Programme, Colombo, Sri Lanka.
Raman GangakhedkarIndian Council of Medical Research, New Delhi, India.
Devidas ChaturbhujDepartment of Microbiology and Immunology, Weill Cornell Medical College, New York, New York, United States of America.
Razia PendseWorld Health Organization, Colombo, Sri Lanka.
Dharshani Iruka RajapakshaNational STD/AIDS Control Programme, Colombo, Sri Lanka.
B B RewariWorld Health Organization South-East Asia Region, New Delhi, India.
Nilmini MalliawaduNational STD/AIDS Control Programme, Colombo, Sri Lanka.
Kanchana JayamannaNational STD/AIDS Control Programme, Colombo, Sri Lanka.
Dammika DombawelaNational STD/AIDS Control Programme, Colombo, Sri Lanka.
Swarali KurleHIV Drug Resistance Laboratory, National AIDS Research Institute, Pune, India.
National Hospital of Sri Lanka · LKNational AIDS Research Institute · INAnti Filariasis Campaign · LKCornell University · USIndian Council of Medical Research · INWorld Health Organization Regional Office for South-East Asia · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe first case of HIV infection in Sri Lanka was reported in 1987 and at the end of 2018 there were 3500 people living with HIV. There have been commendable efforts made towards the detection, treatment, and prevention of HIV in the country. Even though the genetic diversity of HIV has been shown to affect the parameters ranging from detection to vaccine development, there is no data available with respect to the molecular epidemiology of HIV-1 in Sri Lanka.

methodsIn this report we have performed the ancillary analysis of pol gene region sequences (n = 85) obtained primarily for the purpose of HIV-1 drug resistance genotyping. Briefly, dried blood spot specimens (DBS) collected from HIV-1 infected individuals between December 2015 and August 2018 were subjected to pol gene amplification and sequencing. These pol gene sequences were used to interpret the drug resistance mutation profiles. Further, sequences were subjected to HIV-1 subtyping using REGA 3.0, COMET, jPHMM and, RIP online subtyping tools. Moreover, Bayesian phylogenetic analysis was employed to estimate the evolutionary history of HIV-1 subtype C in Sri Lanka.

resultsOur analysis revealed that the majority (51.8%) of pol gene sequences were subtype C. Other than subtype C, there were sequences categorized as subtypes A1, B, D and G. In addition to pure subtypes there were sequences which were observed to be circulating recombinant forms (CRFs) and a few of the recombinants were identified as potential unique recombinants (URFs). We also observed the presence of drug resistance mutations in 56 (65.9%) out of 85 sequences. Estimates of the Bayesian evolutionary analysis suggested that the HIV-1 subtype C was introduced to Sri Lanka during the early 1970s (1972.8).

conclusionThe findings presented here indicate the presence of multiple HIV-1 subtypes and the prevalence of drug resistance mutations in Sri Lanka. The majority of the sequences were subtype C, having their most recent common ancestor traced back to the early 1970s. Continuous molecular surveillance of HIV-1 molecular epidemiology will be crucial to keep track of drug resistance, genetic diversity, and evolutionary history of HIV-1 in Sri Lanka.

Indexed as

Genetic VariationAdolescentAdultAgedAnti-Retroviral AgentsBayes TheoremChildChild, PreschoolDrug Resistance, ViralFemaleHIV-1HIV InfectionsHumansMaleMiddle AgedMutationAnti-Retroviral Agentspol Gene Products, Human Immunodeficiency Virus

Identifiers

PMID32525892
PMCPMC7289380
OpenAlexW3035309778

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.